

Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence

Vascular Medicine
2021, Vol. 26(1) 53–55
© The Author(s) 2020



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1358863X20974452
journals.sagepub.com/home/vmj



Alexandra Kilian¹, Marianne S Clancy², Scott Olitsky²,
James R Gossage³ and Marie E Faughnan^{1,4}

Keywords

arteriovenous malformation, cerebral, hereditary hemorrhagic telangiectasia (HHT), pulmonary, screening, rare diseases

Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease, affecting approximately 1 in 8000 and complicated by vascular malformations (VMs).^{1,2} Patients are at risk of life-threatening complications from VMs in the lungs and brain, which can be treated preventatively.³ We report here the current routine screening practice for lung and brain VMs across North American HHT Centers, with the goal of raising awareness of current standard practices. This is particularly relevant given the existing international controversy regarding brain VM management.

We designed a brief survey (see online supplemental material) to collect information about screening practices for pulmonary arteriovenous malformations (AVMs) and brain VMs in adult and pediatric (age < 18) patients with HHT. The survey, open from September 17 to 20, 2019, was circulated by email to Center Directors at all 28 North American HHT Centers of Excellence (See www.curehht.org). Research ethics board approval for this research was not required, as no patients were involved.

Center Directors from all 28 HHT Centers of Excellence responded (100% response rate). A total of 32 Directors responded, as four Centers have co-directors. For those sites, results agreed and were combined. Directors reported a mean HHT patient experience of 13.4 years (SD = 8.0 years) and were following a mean of 621 patients with HHT (range 70–3500).

Survey results are presented in Table 1. For adult patients with HHT, 100% of Center Directors routinely screened for pulmonary AVMs and brain VMs, with transthoracic contrast echocardiography (TTCE) and brain MRI, respectively. For children, 82% of Center Directors routinely screened for pulmonary AVMs using a variety of protocols including clinical evaluation, supine and upright pulse oximetry, chest radiography, or TTCE, and 89% routinely screened for brain VMs, using MRI.

For adults, routine pulmonary AVM screening is recommended at all HHT Centers, using TTCE, as per HHT

guidelines.⁴ This demonstrates that HHT guidelines recommendations have clearly translated into standard clinical practice across North American HHT Centers of Excellence. In addition, we report that 82% of North American HHT Centers are routinely recommending pulmonary AVM screening for children, in keeping with international guidelines.⁴ The centers not routinely recommending screening for pulmonary AVMs in children reported that they were not routinely caring for pediatric patients. Consistent with guidelines⁴ and subsequent literature,⁵ protocols for screening varied. However, the majority of centers included contrast echocardiography in their screening protocol for children.

At the time of the first HHT International Guidelines (literature review and consensus process in 2006),⁴ there were international disparities in expert opinion and in practice with regards to screening for brain VMs, with North American HHT experts supporting a recommendation for screening, but European experts not recommending. The discussions at that time reflected a cultural difference around the role of screening when preventative therapy is not recommended in all brain VM patients.⁶ This is not surprising and has been described in other clinical situations, such as breast and other cancer screening – where there is

¹Department of Medicine, Division of Respiriology, Toronto HHT Centre, St Michael's Hospital, University of Toronto, Toronto, ON, Canada

²Cure HHT, Monkton, MD, USA

³Department of Medicine, Division of Pulmonary and Critical Care Medicine, Augusta University, Augusta, GA, USA

⁴Li Ka Shing Knowledge Institute and the Keenan Research Centre for Biomedical Science, St Michael's Hospital, University of Toronto, Toronto, ON, Canada

Corresponding author:

Marie E Faughnan, Toronto HHT Centre, Division of Respiriology, Department of Medicine, St Michael's Hospital, University of Toronto, 30 Bond St, Toronto, ON, M5B 1W8, Canada.
Email: marie.faughnan@unityhealth.to

Table 1. Survey results regarding screening practices for lung AVMs and brain VMs from 28 North American HHT Centers of Excellence.

Organ	Age group	Routine screening for AVMs/VMs	Screening test ^a	Screening test comments ^a
Lung	Adult (age ≥ 18 years)	28/28 (100%)	Contrast echocardiogram (28/28, 100%)	–
	Pediatric (age 0–17 years)	23/28 (82%)	Varied tests and protocols	–
Brain	Adult (age ≥ 18 years)	28/28 (100%)	MRI (28/28, 100%)	With contrast (24/28, 86%)
	Pediatric (age 0–17 years)	25/28 (89%)	MRI (25/25, 100%)	With contrast (20/25, 80%)

^aDenominator: number of centers that recommend routine screening.

AVMs, arteriovenous malformations; HHT, hereditary hemorrhagic telangiectasia; MRI, magnetic resonance imaging; VMs, vascular malformations.

higher reported uptake in Americans than in Europeans.⁷ Contributing factors may include cultural values around screening and risk, health systems structure, and screening costs. Recently, the European position was reiterated in a position statement from the European Reference Network for Rare Vascular Diseases (VASCERN) on brain VM screening in adults and children with HHT.⁸

A 2017 systematic review and meta-analysis concluded that the prevalence of brain VMs in patients with HHT is approximately 10%.⁹ The controversy around brain VM screening stems from the risks of treatment for brain VMs, including hemorrhage, neurological deficit, and infection.^{4,6} As such, preventative intervention is not recommended for all patients; the risks of the treatment must be balanced against the risk of spontaneous intracranial hemorrhage without treatment.^{8,10–13} Since publication of the HHT International Guidelines,⁴ the controversy regarding brain VM screening has continued to evolve. Non-HHT brain VM studies, such as the ARUBA trial, have suggested that sporadic brain VMs, if asymptomatic, may be best left untreated.¹⁴ However, the ARUBA trial excluded patients with HHT, and its design has raised many concerns.^{15–17} Thus, its relevance to the HHT brain VM controversy is uncertain. In HHT-specific studies, the average risk of intracranial hemorrhage from brain VMs is estimated to be ‘low’ at 0.5–2% per year.^{8,11,13} However, most of these adult studies are limited by survivor bias, and therefore likely underestimate risk of intracranial hemorrhage. A systematic review and meta-analysis of literature regarding brain VMs in HHT found that a high proportion of patients with HHT with brain VMs will experience symptoms (50%) or AVM-related hemorrhage (20%), further highlighting the role of screening in patients with HHT, which may allow for intervention prior to symptoms or complications.⁹ Patients with HHT with evidence of previous rupture have the highest risk of prospective hemorrhage, in the range of 10% per year.¹³ Other factors, such as imaging phenotype^{12,18} and VM size, may predict hemorrhage, though large prospective studies are pending.

Evidently, interpretation of the literature and perceptions of the risks and benefits related to brain VM screening and treatment differs significantly between Europe and North America; this is also evident in clinical practice. All North American HHT Centers recommend routine screening for

brain VM in adult patients with HHT, whereas only one out of eight VASCERN HHT Centers routinely does so.⁸

We report here that the current standard practice across North American HHT Centers is to routinely recommend screening for pulmonary AVMs and brain VMs in adults and children. Preventative management is currently recommended for pulmonary AVMs.⁴ For brain VMs, routine screening at North American HHT Centers allows for the identification of patients at highest risk of intracranial hemorrhage and for a multidisciplinary team to engage the patient in a risk–benefit discussion regarding brain VM treatment. Future research is needed to identify predictors of intracranial hemorrhage amongst patients with HHT with brain VMs, as well as the outcomes of brain VM treatment in HHT, to help guide clinical decision-making regarding screening and treatment. In addition to brain VM and pulmonary AVM screening, the role of routine screening for hepatic AVMs is a topic of research and consideration. As such, a repeat survey regarding organ VM screening practice, including center-specific reporting, may help characterize changes in clinical practice over time. Moreover, future research should address determinants of quality care for patients with HHT, such as undergoing organ VM screening and considering patient, social, center, and health services factors.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Alexandra Kilian  <https://orcid.org/0000-0002-8715-447X>

Supplementary material

The supplementary material is available online with the article.

References

1. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: A population-based study of prevalence and mortality in Danish patients. *J Intern Med* 1999; 245: 31–39.

2. Donaldson J, McKeever TM, Hall IP, et al. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: A population-based study. *Thorax* 2014; 69: 161–167.
3. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. *N Engl J Med* 1995; 333: 918–924.
4. Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. *J Med Genet* 2011; 48: 73–87.
5. Hosman AE, de Gussem EM, Balemans WA, et al. Screening children for pulmonary arteriovenous malformations: Evaluation of 18 years of experience. *Pediatr Pulmonol* 2017; 52: 1206–1211.
6. Van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of brain arteriovenous malformations: A systematic review and meta-analysis. *JAMA* 2011; 306: 2011–2019.
7. Howard DH, Richardson LC, Thorpe KE. Cancer screening and age in the United States and Europe. *Health Aff (Millwood)* 2009; 28: 1838–1847.
8. Eker OF, Boccardi E, Sure U, et al. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). *Orphanet J Rare Dis* 2020; 15: 165.
9. Brinjikji W, Iyer VN, Wood CP, et al. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: A systematic review and meta-analysis. *J Neurosurg* 2017; 127: 302–310.
10. Nishida T, Faughnan ME, Krings T, et al. Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: Gene–phenotype correlations. *Am J Med Genet A* 2012; 158A: 2829–2834.
11. Willemsse RB, Mager JJ, Westermann CJ, et al. Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic telangiectasia. *J Neurosurg* 2000; 92: 779–784.
12. Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day–60 years. *Neuroradiology* 2005; 47: 711–720.
13. Kim H, Nelson J, Krings T, et al. Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. *Stroke* 2015; 46: 1362–1364.
14. Mohr J, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): A multicentre, non-blinded, randomised trial. *Lancet* 2014; 383: 614–621.
15. Amin-Hanjani S. ARUBA results are not applicable to all patients with arteriovenous malformation. *Stroke* 2014; 45: 1539–1540.
16. Cockroft KM, Jayaraman MV, Amin-Hanjani S, et al. A perfect storm: How a randomized trial of unruptured brain arteriovenous malformations’ (ARUBA’s) trial design challenges notions of external validity. *Stroke* 2012; 43: 1979–1981.
17. Pierot L, Fiehler J, Cognard C, et al. Will a randomized trial of unruptured brain arteriovenous malformations change our clinical practice? *Am J Neuroradiol* 2014; 35: 416–417.
18. Krings T, Kim H, Power S, et al. Neurovascular manifestations in hereditary hemorrhagic telangiectasia: Imaging features and genotype–phenotype correlations. *AJNR Am J Neuroradiol* 2015; 36: 863–870.